Clinical trials: Tocilizumab
Rheumatoid Arthritis
Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis
The purpose of this study is to determine whether tocilizumab changes the cardiovascular risk factors on patients with arthritis rheumatoid.
- Trial name
- TOCRIVAR (NCT01752335)
- Testing
- Braquial ecography
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- Hospital Universitario de Canarias
Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome)
Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19
The overall objective of the study is to determine the therapeutic effect and tolerance of Tocilizumab combined with Dexamethasone in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus…
- Conditions
- Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome), Virus Diseases, Coronaviridae Infections
- Trial name
- TOCIDEX (NCT04476979)
- Testing
- Tocilizumab, Dexamethasone
- Where
- French Guiana
- Volunteers
- 453 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19
A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease
COVID19-associated disease may have different clinical aspects classified in 3 stages. Some patients initially presenting with a non-hypoxemic viral pneumonia (stage 2a) may evolve toward a more severe stage 2b or 3 (acute…
- Trial name
- INFLAMMACOV (NCT04424056)
- Testing
- Anakinra +/- Ruxolitinib (stages 2b/3), Anakinra and Ruxolitinib (Advanced stage 3), Tocilizumab +/- ruxolitinib (stages 2b/3)
- Where
- France
- Volunteers
- 216 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
COVID-19, Virus Diseases
Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction
Our aim is to conduct one trial of personalized immunotherapy in patients with SARS-CoV-2 (COVID-19) associated with organ dysfunction and with laboratory findings of macrophage activation syndrome or immune dysregulation.
- Conditions
- COVID-19, Virus Diseases, Macrophage Activation Syndrome, Corona Virus Infection
- Trial name
- ESCAPE (NCT04339712)
- Testing
- Anakinra, Tocilizumab
- Where
- 17 sites in Greece
- Volunteers
- 102 people
- Sponsor
- Hellenic Institute for the Study of Sepsis
Rheumatoid Arthritis, JAK Inhibitor
Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
The administration of Janus kinase (JAK) inhibitors as well as biological disease-modifying anti-rheumatic drugs has dramatically improved even the clinical outcomes in rheumatoid arthritis (RA) patients with inadequate response…
- Conditions
- Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor, Musculoskeletal Ultrasound
- Trial name
- TRANSFORM (NCT05090410)
- Testing
- filgotinib 200mg/day, subcutaneous tocilizumab 162mg/biweekly
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- Atsushi Kawakami
Covid19
Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)
unicenter, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19.
- Trial name
- COVITOZ-01 (NCT04435717)
- Testing
- Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1, Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses)
- Where
- Spain
- Volunteers
- 26 people
- Sponsor
- Hospital Universitario Ramon y Cajal
Cerebral Venous Thrombosis
Anticoagulation Combined With Tocilizumab for Interleukin-6 Receptor Inhibition in Acute Cerebral Venous Thrombosis
This study aims to evaluate the efficacy and safety of tocilizumab, an interleukin-6 (IL-6) receptor antagonist, combined with standard anticoagulant therapy compared with standard anticoagulant therapy alone in patients with…
- Trial name
- NCT07801638
- Testing
- Tocilizumab, Standard Treatment
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Capital Medical University
Rheumatoid Arthritis
An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy
This is a randomized, double-blind, multi-center, parallel-group study to evaluate the efficacy and safety of subcutaneous (SC) tocilizumab (162 milligrams [mg] every 2 weeks [Q2W]) given as monotherapy and in combination with…
- Trial name
- NCT03155347
- Testing
- Tocilizumab, MTX
- Where
- 20 sites in China
- Volunteers
- 340 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment
This 2 arm study will compare 2 treatment strategies based on tocilizumab in combination with methotrexate or placebo in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT00810199
- Testing
- tocilizumab [RoActemra/Actemra], methotrexate
- Where
- 137 sites in United States, Brazil and 18 more
- Volunteers
- 556 people
- Sponsor
- Hoffmann-La Roche
Myocardial Infarction
Short-Term Application of Tocilizumab Following Myocardial Infarction
Introduction: Interleukin 6 (IL-6) is a cytokine that has a pro-inflammatory effect on the immune system. In acute MI IL-6 levels rapidly increase in response to ischemia and inflammation.
- Trial name
- STAT-MI (NCT02419937)
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Keesler Air Force Base Medical Center
Arthritis,Rheumatoid
Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab
We can speculate that the best responders to tocilizumab should have multiple related elements (Treg CD39, adenosine, IL-35) successfully induced and expressed in order to play its beneficial role.
- Trial name
- NCT02963402
- Testing
- Tocilizumab, Adalimumab
- Where
- Spain
- Volunteers
- 35 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate
This multicenter study with a randomized, double-blind, parallel-group phase will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in combination with methotrexate versus RoActemra/Actemra monotherapy in…
- Trial name
- NCT01587989
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 13 sites in Austria
- Volunteers
- 77 people
- Sponsor
- Hoffmann-La Roche
Adamantinomatous Craniopharyngioma
Tocilizumab in Children With ACP
This study will be conducted in two phases. The first phase (phase 0) will be looking at patients with new or recurrent/ progressed craniopharyngioma tumors.
- Trial name
- NCT03970226
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Colorado, Denver
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis
This open-label study will evaluate the long-term safety and efficacy of RoActemra/Actemra (tocilizumab) in combination with disease modifying anti-rheumatic drugs (DMARDs) in patients with moderate to severe rheumatoid…
- Trial name
- NCT01214733
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 4 sites in South Africa
- Volunteers
- 30 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
This randomized, open-label, parallel-group, multicenter study will evaluate the rate of cardiovascular events with tocilizumab in comparison to etanercept in participants with rheumatoid arthritis (RA).
- Trial name
- NCT01331837
- Testing
- Etanercept, Tocilizumab
- Where
- 428 sites in United States, Argentina and 29 more
- Volunteers
- 3,080 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis
This open-label extension of the JIGSAW studies (WA28117 [NCT01904279] and WA28118 [NCT01904292]) is designed to evaluate the long-term safety and efficacy of subcutaneous (SC) tocilizumab treatment in participants with…
- Trial name
- NCT02165345
- Testing
- Tocilizumab
- Where
- 31 sites in United States, Argentina and 10 more
- Volunteers
- 82 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS
This single arm, open-label study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with active, moderate to severe rheumatoid arthritis who have an inadequate response to non-biologic and/or…
- Trial name
- NCT01149057
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 16 sites in Israel
- Volunteers
- 145 people
- Sponsor
- Hoffmann-La Roche
Heart Transplant
Tocilizumab in Cardiac Transplantation
The purpose of this research study is to see if a study drug called Tocilizumab will, when given with standard anti-rejection medicines, lead to better heart transplantation outcomes at 1 year after the transplant.
- Trial name
- NCT03644667
- Testing
- tocilizumab, Standard of Care Triple IS
- Where
- 20 sites in United States
- Volunteers
- 385 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Giant Cell Arteritis
TARGET GCAT Registry
A longitudinal post-marketing surveillance registry nested within the UK GCA Consortium that assesses the effectiveness and safety of tocilizumab in controlling refractory or relapsing forms of GCA in patients who require…
- Trial name
- NCT04049071
- Where
- 34 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- University of Leeds
Rheumatoid Arthritis
TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment
This open-label, single-arm study will evaluate the efficacy, safety and tolerability of subcutaneously administered tocilizumab in monotherapy and/or in combination with methotrexate and other non-biologic disease modifying…
- Trial name
- NCT02031471
- Testing
- tocilizumab
- Where
- 17 sites in Belgium, Luxembourg
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche